Our Pipeline
Santa Ana is focused on the discovery and development of precision therapeutics for autoimmune and inflammatory diseases. Leveraging deep expertise in discovering and developing proprietary antibodies, we are advancing a portfolio of highly selective and optimized therapeutics for broad patient populations with high unmet needs.
SAB01 (Novel Bispecific Antibody for Mast Cell Diseases)
SAB01 is a novel, first-in-class bispecific antibody for mast cell diseases. By targeting c-KIT and Siglec-6, receptors that are only co-expressed on mast cells, SAB01 is designed to selectively deplete these cells. This selective mechanism is intended to bypass the known adverse events associated with targeting c-KIT on non-mast cells. By restricting depletion to mast cells and avoiding the unwanted off-mast cell tolerability and safety concerns shown by current clinical c-KIT targeted approaches, SAB01 has the potential to be used across a broad range of mast cell-mediated diseases such as urticarias, prurigo nodularis, and food allergy. SAB01 is anticipated to enter Phase 1 in mid-2026.
SAB05 is a novel, first-in-class CD40-targeted glucocorticoid antibody-drug conjugate (ADC) designed to address a broad range of inflammatory autoimmune diseases. SAB05 leverages a dual mechanism of action, combining clinically validated CD40 blockade with the targeted delivery of a highly potent steroid. The ADC's multiple mechanisms are designed to restrict activity to the site of inflammation while simultaneously and safely harnessing the immunosuppressive power of a glucocorticoid. SAB05 has the potential to address a wide range of autoimmune indications and is currently in IND-enabling studies.
Test Header
SAB03 is a novel, highly potent differentiated anti-PD-1 monoclonal antibody designed to aggressively modulate T cells to elicit a disease-modifying effect. SAB03 uniquely depletes and suppresses PD-1 high, medium, and low expressing autoreactive T cells, thereby addressing the full spectrum of pathogenic antigen-reactive T cells for a potentially deeper and more durable clinical response. SAB03 is advancing into IND-enabling activities.
SAB06 is a portfolio of multi-specific antibodies that leverages clinically de-risked pathways in irritable bowel disease and other gastrointestinal diseases. Combining multiple mechanisms, including TL1A, IL-23, and other validated pathways, the SAB06 program is a suite of mono-specific, bispecific, and trispecific antibodies, including combinations thereof. These molecules have the potential for breakthrough efficacy over current clinical approaches. The SAB06 program is currently in lead optimization.